urea and Glucose Intolerance

urea has been researched along with Glucose Intolerance in 3 studies

pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.

Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.

Research

Studies (3)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Decrease in Diastolic Blood Pressure.

Responder is defined as subject with a decrease greater than or equal to 5mm Hg in diastolic blood pressure from baseline to week 24 or last visit. (NCT00569582)
Timeframe: Baseline to Week 24

Improvement in Diabetes and/or Glucose Intolerance.

Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance. (NCT00569582)
Timeframe: Baseline to Week 24

Number of Participants That Experience Changes in Clinical Signs of Hypercortisolemia

The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4. (NCT02160730)
Timeframe: Baseline, Week 4

Number of Participants That Have a Visible Change in Tumor Size

A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment. (NCT02160730)
Timeframe: Baseline, 4 weeks

Number of Participants With a Normalized 24 Hour Urinary Free Cortisol After 4 Weeks

"To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. Normalizing is defined as having urine free cortisol levels within the normal range for that lab value." (NCT02160730)
Timeframe: Baseline, 4 weeks

Number of Participants With Adverse Events

The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability. (NCT02160730)
Timeframe: Baseline, 4 weeks

Change in Clinical Symptoms

Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Change in Diastolic Blood Pressure

Mean diastolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Change in Mean HbA1c Levels Between Baseline and 4 Weeks

HbA1c levels are measured at baseline and at study end, these are averaged across all subjects. (NCT02160730)
Timeframe: Baseline, 4 Weeks

Change in Systolic Blood Pressure

Mean change in systolic blood pressure between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Changes in Serum Cortisol Between Baseline and 4 Weeks

Mean serum cortisol values at baseline and 4 weeks (NCT02160730)
Timeframe: Baseline, 4 weeks

Fasting Glucose at Baseline and 4 Weeks

Mean change between baseline and week 4 of fasting blood glucose levels. (NCT02160730)
Timeframe: Baseline, 4 Weeks

Plasma ACTH at Baseline and 4 Weeks

Mean change in Plasma ACTH between baseline and 4 weeks. (NCT02160730)
Timeframe: Baseline, 4 weeks

Trials

1 trial available for urea and Glucose Intolerance

Other Studies

2 other studies available for urea and Glucose Intolerance